Skip to content

Whole Grain, Gluten-containing Cereal and PROBIOtics to Evaluate Digestive TOLERAance and Immuno-inflammatory Response

Study of the Initiation of Complementary Feeding With a Whole Grain, Gluten-containing Infant Cereal and PROBIOtics to Evaluate Digestive TOLERAance and Immuno-inflammatory Response at the Intestinal Level.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04021303
Acronym
PROBIOTOLERA
Enrollment
172
Registered
2019-07-16
Start date
2019-09-01
Completion date
2021-06-30
Last updated
2020-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Disorder, Immunologic Diseases in Children

Keywords

Gluten, Probiotic, Prebiotic

Brief summary

This study will assess the development of gastrointestinal health in terms of digestive tolerability and immune-inflammatory response at the intestinal level comparing a conventional gluten-free cereal with a new cereal with prebiotics, probiotics and a very moderate amount of gluten. These are products adapted to infant feeding since 4 Months.

Detailed description

In 2008 the ESPGHAN recommended not to give gluten cereals before 4 months but not after 7 months. Although the introduction of gluten in this window was linked to a posible preventive effect on celiac disease, the truth is that it has not been demonstrated. In any case, high exposures to gluten since the 4 months have been associated with a higher incidence of celiac disease and current recommendations propose moderate and progressive exposure to gluten between 4 and 6 months old.

Interventions

DIETARY_SUPPLEMENTExperimental cereal

Cereal containing probiotics, prebiotic fiber and low carbohydrates

DIETARY_SUPPLEMENTConventional cereal

Gluten free conventional cereal (from 4 to 6 months old) and conventional cereal with gluten (from 7 to 12 months old)

Sponsors

Ministerio de Ciencia e Innovación, Spain
CollaboratorOTHER_GOV
Laboratorios Ordesa
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
4 Months to 4 Months
Healthy volunteers
Yes

Inclusion criteria

* Healthy term infants (\>37 weeks) vaginal delivery * Adequate birth weight for gestational age (10-90 percentile) * Infants with normal growth curve (10-90 percentile) * Infants who were breastfeeding for at least 4 weeks, and at least half of the takes have been by breastfeeding. * Infants aged 4 months (+/- 1 week) at the time of study inclusion no longer following breastfeeding, or mixed breastfeeding and if they are breast-feeding, no more than one shot a day. * Availability to continue throughout the study period. * Signature of informed consent by partents/guardians.

Exclusion criteria

* Infants who were born by cesarean section * Infants born from preconception obese mothers * Infants born from diabetic mothers or mothers with gestational diabetes * Infants with a family history of celiac disease (parents or siblings) * Infants who have had or have some type of allergic manifestation or allergic pathology * Infants who have needed antibiotic treatment or have received some type of probiotic (the week before inclusion) * Infants with malformations, diseases or conditions and physical disabilities that cause changes in growth and/or nutritional status * Infants diagnosed with any immune system-related disease (primary immunodeficiency) * Infants with a known allergy and/or intolerance to cow's milk protein * Parents' inability to follow study (at the discretion of the researcher)

Design outcomes

Primary

MeasureTime frameDescription
Digestive toleranceFrom 4 to 12 months oldInfant Gastrointestinal Symptom Questionnaire (IGSQ) developed by Riley et al. to be completed by parents/guardians. It contains 13 ítems.For each item there are 5 possible answers in gradation 1 to 5 points and the result is the sum of all of them with minimum scores of 13 (maximum health status) and maximum of 65

Secondary

MeasureTime frameDescription
Assessment of immune-inflammatory responseAt 4, 6 and 12 months old.Record of the IgA secreted in saliva
Infant infection episodesAt 4, 5, 6, 9 and 12 months old.Specific parent-reported infant symptoms of mild respiratory, gastrointestinal, skin and oropharyngeal infections. Parents will have a dairy to report all symptoms.
Assessment of infant growth: weightAt 4, 5, 6, 9 and 12 months old.Weight measurements in grams to report anthropometric measures
Assessing infant feeding habitsAt 4, 5, 6, 9 and 12 months oldAnalysis of daily intake through a record of food consumption for 24 hours
Infant microbiota studyStool sample collected at 4, 6 and 12 months old.Composition, diversity of microbiota. This procedure will be performed by studying samples of feces.
Assessment of intestinal healthStool sample collected at 4, 6 and 12 months old.Fecal microbiota profile (fecal pH, butyrate, propionate and acetate) determination
Assessment of infant growth: cephalic perimeterAt 4, 5, 6, 9 and 12 months old.Cephalic perimeter measurements in centimeters to report anthropometric measures
Evolution of body compositionAt 4, 5, 6, 9 and 12 months oldAnthropometric measures (brachial perimeter (mm), trichital skin folds and sub-scapular (mm) with compass lipometer)
Medical historyAt 4 months oldRegister of: gestational age, anthropometric measures at birth, lactation data and clinical history of interest
DemographicsAt 4 months oldParents' age, parent education level, habits and parents lifestyle, home and social environment
Assessment of infant growth: lenghtAt 4, 5, 6, 9 and 12 months old.Lenght measurements in centimeters to report anthropometric measures

Countries

Spain

Contacts

Primary ContactRoser De Castellar, MD
RoserDeCastellar@ordesa.es+34 902105243

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026